153704 Vaccination shortages: Recurring error or criminal negligence?

Monday, November 5, 2007: 12:45 PM

C. Lanny Smith, MD, MPH, DTM&H , Depts of Medicine and Family and Social Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
Vaccination against common disease is an effective, low-cost public health measure. Yet some important vaccines, like that for influenza, are quite often in very low supply in communities that are poor or predominantly people of color, like our clinic in the Bronx. Many of the most important vaccines are for various reasons unprofitable, so the corporate pharmaceuticals are not motivated to provide adequate supplies. Conversely, sometimes newly patented, and very expensive vaccines aimed at relatively rare diseases are heavily promoted. Instead of guaranteeing vaccine availability for vaccines in underserved communities, the government has wasted enormous sums on research, development and production for anthrax and smallpox vaccines when there is no need for them. This presentation will discuss the experience of our Bronx community clinic with periodic vaccine shortages, and contrast this neglect with the wasteful smallpox inoculation program several years ago and the continued research and development to reinvent, produce and stockpile vaccines for which there is no public health need.

Learning Objectives:
1. Describe the experience of a Bronx community clinic with vaccine shortages. 2. Discuss the problems with government and corporate priorities with regard to vaccines. 3. Probe the reasons so much resources are given to anthrax and smallpox vaccine development. 4. Project an alternate vision towards public health resource allocation

Keywords: Health Disparities, Public Policy

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.